Yesterday the FDA approved a test that can detect mutations in 324 genes and two genomic signatures in any type of solid tumor (including lung cancer). The Centers for Medicare & Medicaid Services (CMS) also proposed coverage of this test. This one test could allow doctors to better understand the profile of a patient's tumor and prescribe personalized targeted therapies. And, the cost of the test could be covered by Medicare or Medicaid for eligible patients. cms.gov/Newsroom/MediaRelea...
The FDA approves a new test to look at... - Lung Cancer Support
The FDA approves a new test to look at mutations in many types of cancers, including lung cancer
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
DenzieModeratorVolunteer
This is awesome. In the cases where it doesn’t find a useful, Targetable mutation it may tell them what won’t work. Besides saving money not giving a treatment that won’t work it will save the patient unnecessary side effects. Something advocates have pushed strongly for.
scifiknitterBlogger
Great news - this will extend lives!
Thanks Mary, very exciting and hopeful.
Another step in the right direction.
Not what you're looking for?
You may also like...
IMRT appeal denied for a SECOND time - case closed now
said it will be detrimental to him given the tumor is pressing into his heart nor will my dad agree...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-me
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
the full FDA press release:...
Foundation One genetic testing
assistance yesterday as self-patient pay. Less than 24 hours later he got approved for 100 percent...
Farewell to our dear friend Anita
of many. She travelled across the country as a patient advocate, speaking to groups of...